AstraZeneca Announces KALOS, LOGOS Trials Met All Primary Endpoints
AstraZeneca's Fixed-Dose Triple-Combination Therapy BREZTRI AEROSPHERE Meets Primary Endpoints In KALOS And LOGOS Phase III Trials In Asthma
AstraZeneca Reported High-level Results From The Phase 3 KALOS and LOGOS Trials, Showing Fixed-dose Triple-combination Therapy Breztri Aerosphere Met All Primary Endpoints In Patients With Uncontrolled Asthma
AstraZeneca's Asthma Drug Improves Lung Function in Late-stage Studies
AstraZeneca Director Invests in Company Shares
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading
